目的 探討復(fù)方皂礬丸聯(lián)合注射用阿扎胞苷治療骨髓增生異常綜合征的臨床療效。方法 選取青島市第八人民醫(yī)院在2023年2月—2025年1月收治的骨髓增生異常綜合征患者，共計68例。將所有患者按隨機數(shù)字表法分為對照組和治療組，每組34例。對照組皮下注射注射用阿扎胞苷75 mg/m²，1次/d。治療組在對照組基礎(chǔ)上口服復(fù)方皂礬丸，9丸/次，3次/d。4周為1個治療周期，兩組患者持續(xù)治療6個周期。比較兩組治療效果、紅細胞和血小板的輸注總量、生活質(zhì)量、血細胞參數(shù)、血清炎癥指標。結(jié)果 治療后，對照組的總有效率為55.88%，治療組的總有效率為79.41%，組間比較差異顯著（P＜0.05）。治療組紅細胞、血小板輸注總量均明顯高于對照組（P＜0.05）。兩組治療后世界衛(wèi)生組織生存質(zhì)量量表（WGOQOL-100）評分均顯著升高（P＜0.05），治療組治療后的WGOQOL-100評分均高于對照組（P＜0.05）。兩組治療后的中性粒細胞、白細胞計數(shù)、血紅蛋白、血小板計數(shù)均明顯升高（P＜0.05），治療組治療后中性粒細胞、白細胞計數(shù)、血紅蛋白、血小板計數(shù)高于對照組（P＜0.05）。兩組治療后的血清T細胞免疫球蛋白黏蛋白分子-3（Tim3）、低氧誘導(dǎo)因子-1α（HIF-1α）、基質(zhì)細胞衍生因子-1（SDF-1）水平均明顯降低（P＜0.05），且治療組治療后血清Tim3、HIF-1α、SDF-1水平明顯低于對照組（P＜0.05）。結(jié)論 復(fù)方皂礬丸聯(lián)合注射用阿扎胞苷治可提高骨髓增生異常綜合征的療效，改善血細胞指標，提高患者生活質(zhì)量，調(diào)節(jié)造血微環(huán)境。

Objective To investigate the clinical efficacy of Compound Zaofan Pills combined with Azacitidine for injection in treatment of myelodysplastic syndrome. Methods A total of 68 patients with myelodysplastic syndrome admitted to Qingdao Eighth People's Hospital from February 2023 to January 2025 were selected. All patients were divided into control group and treatment group with random number table method, with 34 cases in each group. The control group received sc Azacitidine for injection 75 mg/m², once daily. The treatment group were po administered with Compound Zaofan Pills on the base of the control group, 9 pills/time, 3 times daily. One course was 4 weeks, and two groups continued to receive treatment for 6 courses. The treatment effects, total transfusion volume of red blood cells and platelets, quality of life, blood cell parameters, and serum inflammatory indicators were compared between two groups. Results After treatment, the total effective rate of the control group was 55.88%, and the total effective rate of the treatment group was 79.41%, with significant differences between the groups (P < 0.05). The total transfusion volume of red blood cells and platelets in the treatment group was significantly higher than that in the control group (P < 0.05). The World Health Organization Quality of Life Scale (WGOQOL-100) scores of two groups significantly increased after treatment (P < 0.05), and the WGOQOL-100 scores of the treatment group were higher than those of the control group after treatment (P < 0.05). After treatment, the neutrophil, white blood cell count, hemoglobin, and platelet count in two groups were significantly increased (P < 0.05). The neutrophil, white blood cell count, hemoglobin, and platelet count in the treatment group were higher than those in the control group after treatment (P < 0.05). After treatment, the serum levels of T cell immunoglobulin mucin molecule-3 (Tim3), hypoxia inducible factor-1α (HIF-1α), and stromal cell-derived factor-1 (SDF-1) in two groups were significantly reduced (P < 0.05), and the serum levels of Tim3, HIF-1α, and SDF-1 in the treatment group were significantly lower than those in the control group (P < 0.05). Conclusion Compound Zaofan Pills combined with Azacitidine for injection can improve therapeutic effect in treatment of myelodysplastic syndrome, improve blood cell indicators, enhance quality of life, and regulate the hematopoietic microenvironment.

R977

濟南市衛(wèi)生局科技計劃項目（201820047）